# US 2026/0091129 A1 · Nanocomposite for targeted degradation of pathogenic protein, preparation method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091129 A1
- Document ID: US20260091129A1
- Status: Published application
- Kind: A1
- Application number: 19/111,784
- Filed: 2023-08-17
- Published: 2026-04-02
- Earliest claimed: 2022-09-15
- Assignees: South China University of Technology
- Applicants: South China University of Technology
- Inventors: Yunjiao Zhang; Xiaowan Huang; Ziyang Cao; Xianzhu Yang; Longping Wen
- Web page: https://patentgrep.com/patent/US20260091129A1

## CPC

- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07K 1/107: by chemical modification of precursor peptides
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.

## Claims

### Claim 1

A nanocomposite for targeted degradation of a pathogenic protein, wherein the nanocomposite contains a nanocarrier and a pathogenic protein-targeting binding peptide grafted on the nanocarrier;
wherein the nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids.

### Claim 2 (depends on 1)

The nanocomposite of claim 1, wherein the cationic lipids includes 1,2-dioleoyl-3-trimethylammonium-propane, 2,3-dioleoyloxypropyl-1-trimethylammonium bromide.

### Claim 3 (depends on 1)

The nanocomposite of claim 1, wherein the mass ratio of the cationic lipids to the maleimide-polyethylene glycol-polylactic acid is (5-40): 100.

### Claim 4 (depends on 1)

The nanocomposite according to of claim 1, wherein the pathogenic protein includes mutant p53 protein and mutant huntingtin protein;
the mutant p53 protein contains at least one mutation site selected from the group consisting of S241F, R175H, R248W, and R280K mutation sites; and
the mutant huntingtin protein includes Htt-(Q74) mutation type.

### Claim 5 (depends on 4)

The nanocomposite of claim 4, wherein the mutant p53 protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.1; and
the mutant huntingtin protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.2.

### Claim 6

A method for preparing a nanocomposite for targeted degradation of a pathogenic protein, the nanocomposite containing a nanocarrier and a pathogenic protein-targeting binding peptide grafted on the nanocarrier, wherein the method includes:
subjecting the pathogenic protein-targeting binding peptide to undergo a click reaction with a solution containing the nanocarrier, and performing dialysis, ultrafiltration and concentration on the reaction product in sequence to obtain the nanocomposite for targeted degradation of the pathogenic protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the molar ratio of the pathogenic protein-targeting binding peptide to the nanocarrier is (1-3): 1.

### Claim at position 8

8-10: (canceled)

### Claim 11 (depends on 6)

The method claim 6, wherein the cationic lipids includes 1,2-dioleoyl-3-trimethylammonium-propane, 2,3-dioleoyloxypropyl-1-trimethylammonium bromide.

### Claim 12 (depends on 6)

The method of claim 6, wherein the mass ratio of the cationic lipids to the maleimide-polyethylene glycol-polylactic acid is (5-40): 100.

### Claim 13 (depends on 6)

The method of claim 6, wherein the pathogenic protein includes mutant p53 protein and mutant huntingtin protein;
the mutant p53 protein contains at least one mutation site selected from the group consisting of S241F, R175H, R248W, and R280K mutation sites; the mutant huntingtin protein includes Htt-(Q74) mutation type.

### Claim 14 (depends on 13)

The method of claim 13, wherein the mutant p53 protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.1; the mutant huntingtin protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.2.

### Claim 15 (depends on 6)

The method of claim 6, further comprising:
preparing an anti-tumor nanodrug using the nanocomposite.

### Claim 16 (depends on 6)

The method of claim 6, further comprising:
preparing a Huntington's disease inhibiting drug using the nanocomposite.

### Claim 17

An anti-tumor nanodrug comprising:
a nanocomposite containing a nanocarrier and a pathogenic protein-targeting binding peptide grafted on the nanocarrier;
wherein the nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; and
anti-tumor active ingredient(s) loaded in the nanocomposite;
wherein, the anti-tumor active ingredient(s) include(s) cisplatin Pt(IV) prodrug.

### Claim 18 (depends on 17)

The anti-tumor nanodrug of claim 17, wherein the cationic lipids includes 1,2-dioleoyl-3-trimethylammonium-propane, 2,3-dioleoyloxypropyl-1-trimethylammonium bromide.

### Claim 19 (depends on 17)

The anti-tumor nanodrug of claim 17, wherein the mass ratio of the cationic lipids to the maleimide-polyethylene glycol-polylactic acid is (5-40): 100.

### Claim 20 (depends on 17)

The anti-tumor nanodrug of claim 17, wherein the pathogenic protein includes mutant p53 protein and mutant huntingtin protein;
the mutant p53 protein contains at least one mutation site selected from the group consisting of S241F, R175H, R248W, and R280K mutation sites; and
the mutant huntingtin protein includes Htt-(Q74) mutation type.

### Claim 21 (depends on 20)

The anti-tumor nanodrug of claim 20, wherein the mutant p53 protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.1; and
the mutant huntingtin protein-targeting binding peptide has an amino acid sequence of SEQ ID NO.2.

### Claim 22 (depends on 17)

The anti-tumor nanodrug of claim 17, wherein the anti-tumor nanodrug is formed by:
self-assembling a solution containing maleimide-polyethylene glycol-polylactic acid, cationic lipids and anti-tumor active ingredient(s) in a buffer to obtain a solution containing drug-loaded nanoparticles; and
subjecting the solution containing drug-loaded nanoparticles to undergo a click reaction with the protein-targeting binding peptide, and performing dialysis, ultrafiltration and concentration on the reaction product in sequence to obtain the anti-tumor nanodrug.
